Surgical TreAtment for Obesity Related Disease and Onco-Metabolic Surgery
Key facts
- Where
- Seoul, South KoreaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 69 years old?
Source: NCT04284943, who can take part
Where in South Korea
- Korea University Anam HospitalSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Korea University Anam Hospital
- Trial code
- NCT04284943
- Record updated
- 7 August 2026
- Original description
This is a prospective, multi-center, randomized controlled trial to compare Billroth II reconstruction versus conventional Roux-en-Y reconstruction versus long limb Roux-en-Y reconstruction for glycemic control in patients with concurrent type 2 diabetes and gastric cancer.Read full original descriptionShow less
A Randomized Controlled Trial Comparing Billroth II Reconstruction Versus Conventional Roux-en-Y Reconstruction Versus Long Limb Roux-en-Y Reconstruction for Glycemic Control in Patients With Concurrent Type 2 Diabetes and Gastric Cancer
This is a prospective, multi-center, randomized controlled trial to compare Billroth II reconstruction versus conventional Roux-en-Y reconstruction versus long limb Roux-en-Y reconstruction for glycemic control in patients with concurrent type 2 diabetes and gastric cancer.
Inclusion: Distal gastric adenocarcinoma diagnosed pathologically under preoperative endoscopic biopsy, and clinical stage I-II; Body mass index ≥ 23 kg/m2; Type 2 diabetes and HbA1c ≥ 6.5%.
Exclusion: Prior gastrointestinal surgery including splenectomy, hepatobiliary and pancreatic surgery (except hemorrhoidectomy, herniorrhaphy, and appendectomy); Abdominal, thoracic, pelvic and/or obstetric-gynecologic surgery within 3 months; Cardiovascular conditions including significant known CAD, uncompensated congestive heart failure, history of stroke, or uncontrolled hypertension. Subjects with CAD that have been successfully treated with CABG or PCI, and have no evidence of active ischemia are eligible; Use of investigational therapy or participation in any other clinical trial within 3 months; Kidney disease including renovascular hypertension, renal artery stenosis, or end-stage renal disease; Chronic liver disease including liver cirrhosis, alpha-1 antitrypsin deficiency; Gastrointestinal disorders including inflammatory bowel disease (Crohn's disease or ulcerative colitis) or any malabsorptive disorders; Psychiatric disorders including dementia, active psychosis, history of suicide attempts, alcohol or drug abuse within 12 months; Severe pulmonary disease defined as FEV1 <50% of predicted value; Malignancy within 5 years (except squamous cell and basal cell cancer of the skin). Subjects diagnosed with early or stage I cancer than have been successfully treated are eligible per investigator discretion; Any condition or major illness that, in the investigator's judgement, places the subject at undue risk by participating in the study; Anemia defined as hemoglobin less than 8 in females and 10 in males; Insulin usage for glycemic control at the time of screening evaluation; Frail elderly (Rockwood Clinical Frailty Scale ≥5); Unable to understand the risks, realistic benefits and compliance requirements of each program; Geographic inaccessibility; Pregnancy.